Resistant migraine (ResM) Vs Refractory migraine (RefM) Vs Non-resistant/non-refractory migraine (NRNRM)
Posted on December 05 2024,
This content is sponsored by
Resistant vs. Refractory Migraine
REFINE study reveals distinct clinical entities with progressively increasing comorbidity burden
Source: The REFINE study published in The Journal of Headache and Pain
The REFINE study showed that resistant migraine (ResM) and refractory migraine (RefM) represent distinct clinical entities with progressively increasing burden of comorbidities. The study found a continuum where RefM patients showed the highest prevalence of comorbidities (particularly psychiatric conditions), followed by ResM, and then non-resistant/non-refractory (NRNRM) patients. These differences persisted even when analyzing only chronic migraine patients, suggesting that treatment resistance/refractoriness is independent of migraine chronicity.
689
Total Patients
Comprehensive study population
51.4%
Non-Resistant/Non-Refractory
354 patients with standard migraine
38.0%
Resistant Migraine
262 patients failed ≥3 drug classes
10.4%
Refractory Migraine
73 patients failed ALL drug classes
Key Definitions
- Non-Resistant/Non-Refractory (NRNRM): Patients who respond to standard migraine treatments
- Resistant Migraine (ResM): ≥8 debilitating headache days/month for ≥3 months, failed ≥3 preventive drug classes
- Refractory Migraine (RefM): ≥8 debilitating headache days/month for ≥8 months, failed ALL available preventive drug classes
These findings suggest the need for differentiated clinical approaches and highlight the importance of addressing both the primary condition and associated comorbidities...specifically in the management of resistant and refractory cases.
Disease Characteristics and Comorbidities
| Disease Characteristics | Non-Resistant/Non-Refractory (NRNRM) | Resistant Migraine (ResM) | Refractory Migraine (RefM) |
|---|---|---|---|
| Diagnostic Criteria | Basic ICHD-III migraine criteria | ICHD-III migraine with/without aura or chronic migraine | ICHD-III migraine with/without aura or chronic migraine |
| Headache Frequency | Any frequency | ≥8 debilitating headache days/month | ≥8 debilitating headache days/month |
| Duration Requirement | None specified | At least 3 months | At least 8 months |
| Treatment Response | Responds to standard treatments | Failed ≥3 preventive drug classes | Failed ALL available preventive drug classes |
| Study Demographics | 354 patients (51.4%) | 262 patients (38.0%) | 73 patients (10.4%) |
| Chronic Migraine Prevalence | 40.1% | 70.2% | 83.6% |
| Multiple Comorbidities | ≥2: 56.8% ≥3: 36.4% ≥4: 26.2% |
≥2: 70.4% ≥3: 49.4% ≥4: 35.0% |
≥2: 80.6% ≥3: 69.4% ≥4: 55.6% |
| Key Psychiatric Comorbidities | Depression: 15.8% Anxiety: 11.3% Sleep disorders: 28.0% |
Depression: 34.1% Anxiety: 25.2% Sleep disorders: 40.3% |
Depression: 39.7% Anxiety: 35.7% Sleep disorders: 33.3% |
| Other Notable Comorbidities | Trigger points: 12.4% TMJ disorders: 10.7% Thyroiditis: 3.7% |
Trigger points: 21.3% TMJ disorders: 13.6% Thyroiditis: 9.2% |
Trigger points: 33.3% TMJ disorders: 23.6% Thyroiditis: 12.5% |
| Median Disease Duration | 24 years (IQR 16-33) | 31 years (IQR 20-40) | 34 years (IQR 26-38) |
Key Findings: Progressive Comorbidity Burden
- Psychiatric conditions: Depression rates increase from 15.8% (NRNRM) to 39.7% (RefM)
- Multiple comorbidities: ≥4 conditions rise from 26.2% to 55.6% across groups
- Chronic migraine prevalence: Dramatically increases from 40.1% to 83.6%
- Disease duration: Longer disease history correlates with treatment resistance
Clinical Management Approaches
| Clinical Management | Non-Resistant/Non-Refractory (NRNRM) | Resistant Migraine (ResM) | Refractory Migraine (RefM) |
|---|---|---|---|
| Treatment Approach | Standard migraine preventive treatments | Advanced preventive treatments; Consider combination therapy | Requires highly individualized treatment plan; May need novel therapeutic approaches |
| Comorbidity Management | Standard screening and treatment of comorbidities | Active management of comorbidities; Regular psychiatric evaluation recommended | Aggressive management of comorbidities; Integrated multi-disciplinary care essential |
| Monitoring Needs | Regular follow-up as needed | Close monitoring of treatment response and comorbidities | Very frequent monitoring; Regular assessment of treatment strategy |
| Care Setting | Primary care or general neurology | Headache specialist recommended | Tertiary headache center with multi-disciplinary team |
| Prognosis Factors | Generally favorable with standard treatment | May improve with targeted treatment of both migraine and comorbidities | More challenging prognosis; Focus on quality of life improvement |
| Prevention Strategy | Standard lifestyle modifications and trigger avoidance | Aggressive lifestyle modification; Early intervention for comorbidities | Comprehensive lifestyle and behavioral interventions; Intensive comorbidity management |
Clinical Implications
- Individualized care: Treatment plans must be tailored to resistance level and comorbidity profile
- Multidisciplinary approach: RefM patients require integrated teams including psychiatry and behavioral health
- Early intervention: Aggressive comorbidity management may prevent progression to refractory status
- Specialized care: Treatment-resistant cases benefit from tertiary headache centers
Fri, Jul 11, 25
Migraine and Depression: Shared Brain Mechanisms
Learn why migraine and depression are linked through shared brain pathways. 2025 research reveals genetic connections and dual-action treatments for both.
Read MoreMon, Jul 07, 25
Chronic Pain and Brain Gene Expression
New study proves chronic pain is biological. Brain immune cells drive pain, offering hope for targeted migraine and chronic pain treatments.
Read MoreSat, Jul 05, 25
Migraine & White Matter Hyperintensities
Migraine and white matter hyperintensities: Recent studies show NO association. Large-scale 2023-2025 research contradicts older findings. Important clinical implications explained.
Read More